The active pharmaceutical ingredients (API) manufacturing market is poised to achieve significant growth amid rapid technological advancements in the next few years, according to expert forecasts published in a new report by The Business Research Company.

There are 6.8 million children and adults with autism in America, and the Unites States is the largest market for autism treatment programs.

The increase in development of biologics (drugs made from living organisms) is driving the adoption of biosimilars, which is a cheaper alternative with the same efficacy when compared to biologics.

Age-related macular degeneration (AMD) is a chronic, progressive, and severe disease of the central retina and is the leading cause of irreversible vision loss.

Part of the weight loss market was hit hard in 2020 as the COVID-19 pandemic and ensuing recession forced the closure of health clubs and many retail weight loss centers.

After the great shock exerted by the COVID-19 pandemic on the global economy, as well as on world trade, 2021 fortunately marked the beginning of a path to recovery.

The global biologics market is expected to see a 12% growth rate and reach $420.55 billion by 2025, according to a new report by The Business Research Company.

Because the pegfilgrastim biosimilars market is highly concentrated with only a few large players, gaining an in-depth understanding of the top competitors and their key strategies is crucial. A new report by The Business Research Company provides detailed information on the pegfilgrastim biosimilars competitive landscape. Read on to learn key insights from the report.

The COVID-19 pandemic has sped up the adoption of artificial intelligence (AI) in the pharma market in domains such as healthcare.

One of the new classes of vaccines, mRNA-based vaccines facilitate cells in the body to make specific proteins for triggering an immune response, further producing antibodies against a specific disease.